LifeGlue Technologies, a spin-out from Tampere University, has successfully raised EUR 705,000 in seed funding from business angels across Finland, Estonia, and Lithuania, with additional support from Innovestor. This funding is aimed at advancing the pharmaceutical-grade production of Glue4Life, a gel that helps cells grow and provides a structured environment in laboratory settings.
LifeGlue's production efforts will enable the development of its innovative materials for companies working in tissue engineering. The gel is made from hyaluronic acid, ensuring it meets Good Manufacturing Practice (GMP) standards needed for clinical trials. LifeGlue started commercial operations in December 2024 and is serving 15 paying customers in Europe, the US, and Australia.
The funding allows LifeGlue to scale up its production capabilities, positioning the company for significant entry into the tissue engineering and regenerative medicine markets.
